se of exercise and medical therapies to improve cardiac function among patients with exertional shortness of breath due to lung congestio

Phase 3

Completed

• Conditions: Diastolic dysfunction, heart failure with preserved ejection fraction (HFpEF); Cardiovascular - Other cardiovascular diseases

• Registration Number: ACTRN12610001087044
• Lead Sponsor: niversity of Queensland

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-12-13
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

We intend to recruit patients who are found to demonstrate increased E/e’ at exercise echo with reduced exercise capacity. Exercise intolerance will be defined by either a previous exercise test with exercise capacity reduced >20% from published normal ranges or reduction of predicted exercise capacity based on the Duke Activity Status questionnaire

Exclusion Criteria

(1) atrial fibrillation (variations in cycle length may be problematic for calculating E/E’), (2) ischemia evidenced by angina or a positive diagnostic test (where improvement of exercise capacity may be due to reduction of ischemia), (3) patients already on nitrate, ivabradine or spironolactone and (4) patients with renal impairment (creatinine > 0.18) or hyperkalaemia (> 5.5 mmol/L).

Study & Design

• Study Type: Interventional
• Study Design: Not specified